Shibata K, Nakatsumi Y, Kasahara K, Bando T, Fujimura M, Matsuda T
Department of Internal Medicine (III), Kanazawa University School of Medicine, Japan.
J Cancer Res Clin Oncol. 1996;122(7):437-42. doi: 10.1007/BF01212885.
Thrombocytopenia induced by carboplatin combined with etoposide for elderly lung cancer patients was analyzed in relation to the predicted thrombocytopenia by the equations advocated by Egorin et al. and Taguchi et al. The thrombocytopenia actually observed was strongly correlated with and significantly more severe than that predicted if carboplatin had been administered as a single agent. The AUC (area under the curve) of carboplatin predicted by Calvert's equation significantly affected the degree of thrombocytopenia. These data suggested that dosing of carboplatin should be determined individually on the basis of renal function, as recommended earlier. The reason for the enhancement of thrombocytopenia is yet to be determined in future trials.
分析了卡铂联合依托泊苷治疗老年肺癌患者所致的血小板减少情况，并与Egorin等人和Taguchi等人提出的公式预测的血小板减少情况进行了比较。实际观察到的血小板减少与卡铂单药给药时预测的情况密切相关且明显更严重。Calvert公式预测的卡铂曲线下面积（AUC）显著影响血小板减少的程度。这些数据表明，应如先前推荐的那样，根据肾功能个体化确定卡铂的给药剂量。血小板减少增强的原因有待未来试验确定。
